Stockscreener 앱 받기
21.87
3.49%
-0.79
시간 외 거래:
21.70
-0.17
-0.78%
전일 마감가:
$22.66
열려 있는:
$22.66
하루 거래량:
365.05K
Relative Volume:
0.75
시가총액:
$1.07B
수익:
-
순이익/손실:
$-85.21M
주가수익비율:
-11.57
EPS:
-1.89
순현금흐름:
$-68.53M
1주 성능:
-4.91%
1개월 성능:
+2.68%
6개월 성능:
-0.59%
1년 성능:
-0.64%
1일 변동 폭
$21.79
$23.41
1주일 범위
$21.12
$24.38
52주 변동 폭
$13.30
$30.03
Enliven Therapeutics Inc Stock (ELVN) Company Profile
명칭
Enliven Therapeutics Inc
전화
720-647-8519
주소
6200 LOOKOUT ROAD, BOULDER
ELVN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
21.87 | 1.36B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 개시 | Goldman | Buy |
| 2024-12-13 | 개시 | BTIG Research | Buy |
| 2024-09-09 | 개시 | H.C. Wainwright | Buy |
| 2024-06-11 | 개시 | Robert W. Baird | Outperform |
| 2024-04-09 | 개시 | Mizuho | Buy |
| 2023-03-29 | 개시 | Jefferies | Buy |
모두보기
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
What drives Enliven Therapeutics Inc. stock priceFastest-growing stock picks - Autocar Professional
Can Enliven Therapeutics, Inc. (ELVN) Climb 75.66% to Reach the Level Wall Street Analysts Expect? - MSN
What analysts say about Enliven Therapeutics Inc. stockTriple-digit wealth increases - Autocar Professional
Enliven Therapeutics Inc. Stock Analysis and ForecastConsistently superior profits - jammulinksnews.com
Is Enliven Therapeutics Inc. a good long term investmentExplosive earning power - jammulinksnews.com
Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Enliven Therapeutics (ELVN) - The Globe and Mail
Enliven Therapeutics’ Promising Phase 1a/1b Study on ELVN-002 in HER2+ Cancers - TipRanks
Will Enliven Therapeutics Inc. stock split in the near futureTop Performing Low Risk Stocks - Newser
Enliven Therapeutics’ Promising CML Treatment: A Study Update - TipRanks
Enliven Therapeutics’ Promising CML Study Update: What Investors Need to Know - MSN
What makes Enliven Therapeutics Inc. stock price move sharplyFree Investment Community - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityInsider Strategy Insight - Newser
(ELVN) Proactive Strategies - news.stocktradersdaily.com
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionDefensive Stock Picks with Upside - Newser
Enliven Therapeutics CFO Hohl sells $22,655 in shares - Investing.com Australia
Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Target Price at $41.20 - Defense World
Enliven Therapeutics Breaks Above 200-Day Moving AverageBullish for ELVN - Nasdaq
Enliven Therapeutics COO Patel sells shares worth $131950 By Investing.com - Investing.com Canada
Enliven Therapeutics COO Patel sells shares worth $131950 - Investing.com
HC Wainwright Brokers Increase Earnings Estimates for ELVN - Defense World
(ELVN) Long Term Investment Analysis - news.stocktradersdaily.com
Enliven Therapeutics Advances CML Treatment with ELVN-001 Study - TipRanks
Enliven Therapeutics (NASDAQ:ELVN) Shares Up 7.9% Following Analyst Upgrade - Defense World
Enliven Therapeutics stock price target raised to $48 from $40 at H.C. Wainwright - Investing.com Canada
Enliven Therapeutics’ Promising CML Study: A Potential Game-Changer? - TipRanks
Enliven Therapeutics Advances in HER2 Mutant Lung Cancer Study - TipRanks
GAMMA Investing LLC Grows Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - Defense World
Enliven Therapeutics Appoints New Directors at Annual Meeting - TipRanks
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $37.20 Average Target Price from Brokerages - Defense World
Enliven Therapeutics CEO Kintz sells $277k in shares By Investing.com - Investing.com India
Enliven Therapeutics CEO Kintz sells $277k in shares - Investing.com
Enliven grosses $230M from stock sale - BizWest
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - Eastern Progress
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data - MSN
Enliven Raises $230m To Fund Scemblix Leukemia Challenger - insights.citeline.com
Enliven Therapeutics (NASDAQ:ELVN) Given New $52.00 Price Target at Robert W. Baird - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up on Analyst Upgrade - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at The Goldman Sachs Group - Defense World
10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey
Enliven Therapeutics Inc (ELVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):